Stockreport

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA f [Read more]